2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119810B
    Seletracetam lithium bromide 2024584-38-9 98%
    Seletracetam (Ucb 44212) lithium bromide, an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy.
    Seletracetam lithium bromide
  • HY-119885A
    (±)-Amiflamine 77502-96-6 99.23%
    (±)-Amiflamine (FLA 336) is a potent monoamine oxidase-A (MAO-A) inhibitor with a pIC50 of 5.57.
    (±)-Amiflamine
  • HY-119910A
    Aminoquinol 10023-54-8 98%
    Aminoquinol is a GFRα-1 agonist. Aminoquinol exhibits neurotrophic effects similar to GDNF and induces Ret autophosphorylation in Neuro-2A cells. Aminoquinol can be used in research related to Parkinson's disease.
    Aminoquinol
  • HY-119926A
    13-Hydroxylupanine hydrochloride 6809-89-8 98%
    13-Hydroxylupanine Hydroxylupanine is the typical alkaloid profile of sweet lupins. 13-Hydroxylupanine Hydroxylupanine blocks ganglionic transmission, decreases cardiac contractility and contracts uterine smooth muscle.
    13-Hydroxylupanine hydrochloride
  • HY-119943B
    (R)-PF-06256142 1609583-15-4 99.59%
    (R)-PF-06256142 is the R enantiomer of PF-06256142 with low active. PF-06256142 is a potent and selective orthosteric D1 receptor agonist that can reduce receptor desensitization relative to dopamine and other catechol-containing agonists.
    (R)-PF-06256142
  • HY-119980A
    Fluphenazine dimaleate 3093-66-1 98%
    Fluphenazine dimaleate is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dimaleate blocks neuronal voltage-gated sodium channels. Fluphenazine dimaleate acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dimaleate can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dimaleate can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
    Fluphenazine dimaleate
  • HY-119980B
    Fluphenazine hydrochloride 1254-47-3 98%
    Fluphenazine hydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine hydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine hydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine hydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine hydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
    Fluphenazine hydrochloride
  • HY-120081B
    Metixene hydrochloride 1553-34-0 98%
    Metixene (Piperidine) hydrochloride hydrate is an anticholinergic and antiparkinsonian agent. Metixene hydrochloride potently inhibits binding of quinuclidinyl benzilate (QNB) with the muscarinic receptor, IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene hydrochloride can be used for the research of parkinsonian.
    Metixene hydrochloride
  • HY-120160A
    Darglitazone Sodium 149904-87-0 98%
    Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research.
    Darglitazone Sodium
  • HY-120206B
    Brasofensine sulfate 171655-92-8 98%
    Brasofensine (BMS-204756) sulfate is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research.
    Brasofensine sulfate
  • HY-120403A
    Pramiverine hydrochloride 14334-41-9 98%
    Pramiverine hydrochloride is a long-acting anticholinergic agent. Pramiverine hydrochloride exerts a tonic inhibitory effect on esophageal peristalsis during swallowing. Pramiverine hydrochloride can be used for research on gastrointestinal spasms.
    Pramiverine hydrochloride
  • HY-120410A
    DL-4662 hydrochloride 98%
    DL-4662 hydrochloride is a psychoactive substance.
    DL-4662 hydrochloride
  • HY-120475B
    PBT434 free base 1232840-87-7 98%
    PBT434 (ATH434) free base is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 free base can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 free base inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 free base prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 free base has the potential for the research of Parkinson’s disease (PD).
    PBT434 free base
  • HY-120679A
    XK469 sodium 157434-99-6 98%
    XK469 (NSC 697887) sodium is a quinoxaline-based topoisomerase II inhibitor. XK469 sodium exhibits antiproliferative activity against neuroblastoma cells. XK469 sodium can be used in the research of neuroblastoma.
    XK469 sodium
  • HY-120782A
    Yhhu-3792 hydrochloride 2624336-93-0 98%
    Yhhu-3792 hydrochloride is a Notch activator. Yhhu-3792 hydrochloride enhances the self-renewal capability of neural stem cells (NSCs). Yhhu-3792 hydrochloride promotes the expression of Hes3 and Hes5. Yhhu-3792 hydrochloride increases the spatial and episodic memory abilities of mice. Yhhu-3792 hydrochloride can be used for the study of neurodegenerative diseases (such as Alzheimer's disease) or for neural regeneration after brain injury .
    Yhhu-3792 hydrochloride
  • HY-120994A
    Rp-8-CPT-cAMPS 129735-01-9 98%
    Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI.
    Rp-8-CPT-cAMPS
  • HY-120994B
    Sp-8-CPT-cAMPS 129693-13-6 98%
    Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold.
    Sp-8-CPT-cAMPS
  • HY-121027A
    Anagyrine hydrochloride 74195-83-8 98%
    Anagyrine ((-)-Anagyrine) hydrochloride is a quinolizidine alkaloid that has been found in Lupinus albus. Anagyrine hydrochloride binds to muscarinic and nicotinic acetylcholine receptors with IC50 values of 132 and 2096 µM respectively. Anagyrine hydrochloride is a potent and effective desensitizer of nAChR, and Anagyrine hydrochloride can directly, without metabolism, desensitize nAChR.
    Anagyrine hydrochloride
  • HY-121053A
    Adatanserin hydrochloride 144966-96-1 98%
    Adatanserin hydrochloride is a high affinity, selective and partial agonist for the 5-HT1A receptor with a Ki of 1 nM. Adatanserin hydrochloride is a moderate affinity 5-HT2 receptor antagonist with a Ki of 73 nM. Adatanserin hydrochloride shows significant anxiolytic and antidepressant activity in an animal conflict model.
    Adatanserin hydrochloride
  • HY-121095A
    Bizine dihydrochloride 1808112-57-3 99.90%
    Bizine dihydrochloride, a Phenelzine analogue, is a potent and selective LSD1 inhibitor, with a b>Ki of 59 nM. Bizine dihydrochloride can modulate bulk histone methylation in cancer cells. Bizine dihydrochloride shows neuroprotective effects.
    Bizine dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity